Fonte: The Lancet. Unidades: FMRP, IME
Assuntos: COVID-19, TROMBOCITOPENIA, BIOESTATÍSTICA
ABNT
RAMACCIOTTI, Eduardo et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. The Lancet, v. 399, n. 10319, p. 50-59, 2022Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(21)02392-8. Acesso em: 03 nov. 2024.APA
Ramacciotti, E., Agati, L. B., Calderaro, D., Aguiar, V. C. R., Spyropoulos, A. C., Oliveira, C. C. C. de, et al. (2022). Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. The Lancet, 399( 10319), 50-59. doi:10.1016/S0140-6736(21)02392-8NLM
Ramacciotti E, Agati LB, Calderaro D, Aguiar VCR, Spyropoulos AC, Oliveira CCC de, Santos JL dos, Volpiani GG, Sobreira ML, Joviliano EE, Bohatch Júnior MS, Fonseca BAL da, Ribeiro MS, Dusilek C, Itinose K, Sanches SMV, Ramos K de AA, Moraes NF de, Tierno PFGMM, Oliveira ALM de, Tachibana A, Chate RC, Santos MVB, Cavalcante BB de M, Moreira RCR, Chiann C, Tafur A, Fareed J, Lopes RD, MICHELLE investigators. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial [Internet]. The Lancet. 2022 ; 399( 10319): 50-59.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1016/S0140-6736(21)02392-8Vancouver
Ramacciotti E, Agati LB, Calderaro D, Aguiar VCR, Spyropoulos AC, Oliveira CCC de, Santos JL dos, Volpiani GG, Sobreira ML, Joviliano EE, Bohatch Júnior MS, Fonseca BAL da, Ribeiro MS, Dusilek C, Itinose K, Sanches SMV, Ramos K de AA, Moraes NF de, Tierno PFGMM, Oliveira ALM de, Tachibana A, Chate RC, Santos MVB, Cavalcante BB de M, Moreira RCR, Chiann C, Tafur A, Fareed J, Lopes RD, MICHELLE investigators. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial [Internet]. The Lancet. 2022 ; 399( 10319): 50-59.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1016/S0140-6736(21)02392-8